Completed PHASE2 INTERVENTIONAL 3-arm NCT00991861

Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis

Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II

Sponsor: Almirall, S.A.

Conditions Actinic Keratosis

Interventions LAS106521 LAS41007 b.i.d. LAS41007 o.d.

Updated 5 times since 2017 Last updated: May 28, 2015 Started: Aug 31, 2009 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Actinic Keratosis, this trial is completed. The trial is conducted by Almirall, S.A. and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Almirall, S.A.

Data source: Almirall, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamburg, Germany